In collaboration with the API Innovation Center’s leadership and communications team, I have worked on several projects for the nonprofit organization.

• I wrote APIIC’s 2025 signature white paper after attending the organization’s November 2024 plenary event. That white paper “enforces the need for a collaborative, multi-faceted approach to enhancing the resilience and security of the U.S. pharmaceutical supply chain.” Read the paper here.

• The second project was a white paper emphasizing “that building a sustainable U.S. generic drug supply chain will require collaboration between government, hospital systems, pharmacies and industry leaders.” The paper was drawn from conversations at a private roundtable event that APIIC hosted in August 2025. Read the paper here.

• My third project with APIIC was the assignment to write its 2026 signature white paper entitled “From Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain.” The report “finds that many of the vulnerabilities stem from long-standing economic pressures in the generic drug market. For decades, generic drug procurement has largely prioritized price above all else.” Read the paper here.